{"entity":{"id":"nct05773820","kind":"trial","name":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of WJB001 in advanced solid tumours, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd., now recruiting.","summary":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05773820 by Wigen Biomedicine Technology (Shanghai) Co., Ltd., with 210 participants planned, started 2023-05-05 and due to reach its primary completion in 2026-08-08. Interventions recorded: WJB001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05773820","url":"https://clinicaltrials.gov/study/NCT05773820"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05773820","phase":"1/2","setting":"A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of WJB001 Capsules in Dose Escalation, Dose Expansion, and Efficacy Expansion in Patients With Advanced Solid Tumors","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","enrolled":210,"outcomes":[]},"route":"/trials/nct05773820/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"wjb001","kind":"drug","name":"WJB001","route":"/drugs/wjb001/"}]}}